{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:26:59Z","timestamp":1788276419509,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Pegmolesatide is a novel synthetic erythropoietin\u2010mimetic agent that binds to and activates the erythropoietin receptor (EPOR), thereby stimulating erythropoiesis. Owing to its erythropoiesis\u2010stimulating activity, it has been included in the latest World Anti\u2010Doping Agency (WADA) Prohibited List as an erythropoietin receptor agonist (S2.1.1). The current analytical approach for pegmolesatide in doping analysis mainly relies on bottom\u2010up nano\u2010liquid chromatography\u2013high\u2010resolution tandem mass spectrometry (LC\u2010HRMS) in serum. Although accurate and sensitive, this approach involves extensive sample preparation and time\u2010consuming LC analysis, which limits its suitability for high\u2010throughput initial testing procedure (ITP). In this study, an enzyme\u2010linked immunosorbent assay (ELISA), termed the EPOR\u2013anti\u2010PEG ELISA, was developed as a screening method for pegmolesatide in urine and serum. The assay employs EPOR as the capture reagent to enrich pegmolesatide, followed by detection of its polyethylene glycol (PEG) moiety using the anti\u2010PEG monoclonal antibody RM105. Method validation included assessment of selectivity, limit of detection (LOD), dynamic range, reliability, and carryover. Under optimized conditions, the assay showed an LOD of 1\u2009ng\/mL in urine, with an adjusted OD\n                    <jats:sub>450<\/jats:sub>\n                    screening cutoff of 0.029. In serum, with an adjusted OD\n                    <jats:sub>450<\/jats:sub>\n                    screening cutoff of 0.243, the LOD was 2\u2009ng\/mL, which was lower than the limit of identification (LOI) of 7\u2009ng\/mL determined by LC\u2010HRMS. Overall, this ELISA provides a streamlined, cost\u2010effective, and high\u2010throughput screening approach for pegmolesatide and may serve as a practical complement to the LC\u2010HRMS method in doping analysis.\n                  <\/jats:p>","DOI":"10.1002\/dta.70113","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:32:21Z","timestamp":1781919141000},"page":"1177-1185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of an Enzyme\u2010Linked Immunosorbent Assay for Pegmolesatide in Doping Analysis: An Initial Testing Method"],"prefix":"10.1002","volume":"18","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"},{"name":"School of Sport Science Beijing Sport University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3922-7282","authenticated-orcid":false,"given":"Chengshuai","family":"Niu","sequence":"additional","affiliation":[{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-5358","authenticated-orcid":false,"given":"Xinmiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Beijing Anti\u2010Doping Laboratory Beijing Sport University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.26648.1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000356193"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90014-7"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.08.003"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868080-00009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.05.007"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-13-95"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06078-1"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S23270"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-172320"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.02.007"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-303271"},{"key":"e_1_2_9_14_1","unstructured":"World Anti\u2010Doping Agency \u201cThe Prohibited List 2026 \u201d (2025) accessed April 20 2026 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2025\u201009\/2026list_en_final_clean_september_2025.pdf."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2016.07.014"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01770-y"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3931"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2011.07.012"},{"key":"e_1_2_9_19_1","unstructured":"World Anti\u2010Doping Agency \u201cWADA Technical Document \u2013 ISL TD2027VAL: Minimum Requirements for Validation of Analytical Testing Procedures for Doping Control \u201d [cited 2026 April 15]. (2025) https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2025\u201012\/td2027val_eng.pdf."},{"key":"e_1_2_9_20_1","volume-title":"ELISA Development Guide: A Guide for the Use of Antibodies in ELISA Development","author":"R&D Systems, I","year":"2002"},{"key":"e_1_2_9_21_1","unstructured":"Thermo Fisher Scientific \u201cBioconjugation and Crosslinking Technical Handbook: Reagents for Bioconjugation Crosslinking Biotinylation and Modification of Proteins and Peptides \u201d (2022) accessed April 17 2026 https:\/\/www.thermofisher.cn\/cn\/zh\/home\/life\u2010science\/protein\u2010biology\/protein\u2010labeling\u2010crosslinking.html."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/separations9040089"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910318"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8491-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004563219842231"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/28.4.578"},{"key":"e_1_2_9_27_1","unstructured":"World Anti\u2010Doping Agency \u201cWADA Technical Document \u2013 TD2024EPO: Harmonization of Analysis and Reporting of Erythropoietin (EPO)\u2010Receptor Agonists (ERAs) and Transforming Growth Factor\u2010Beta (TGF\u2010\u03b2) Signalling Inhibitors by Polyacrylamide Gel Electrophoretic (PAGE) Analytical Methods \u201d (2024) 11 March 2024 accessed April 30 2026 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2024\u201003\/td2024epo_eng_final.pdf."}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70113","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.70113","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:08:10Z","timestamp":1788275290000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.70113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/dta.70113"],"URL":"https:\/\/doi.org\/10.1002\/dta.70113","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}